X4 Pharmaceuticals develops and commercializes small-molecule therapies for rare immune system disorders, centered on its oral CXCR4 antagonist mavorixafor. The product is approved in the United States for WHIM syndrome and is advancing through pivotal trials for additional indications in chronic neutropenia.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2 | — | -25.7 | — |
| Q3 2025 | 1.8 | — | -29.8 | — |
| Q4 2025 | 2.6 | — | -23.9 | — |
| Q1 2026 | 2.7 | — | -20.2 | — |
| Q2 2026 | 8.8 | 346.3% | -16.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: RF Acquisition Corp II (RFAI), Coincheck Group N.V. (CNCK), SCHMID Group N.V. (SHMD), Escalade, Incorporated (ESCA), GBank Financial Holdings Inc. (GBFH), iHeartMedia, Inc. (IHRT)